Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm Lupeng Pharmaceutical Ltd for the next-generation Bruton’s tyrosine kinase (BTK) inhibitor, LP-168. According to the terms of the agreement, Hansoh will assume responsibility for research and development, manufacturing, regulatory filings, and commercialization of LP-168 for all non-oncology indications within China, including Hong Kong, Macau, and Taiwan.
Hansoh has committed to an upfront payment to Lupeng, along with development, regulatory, and marketing milestone payments that could reach a total of RMB 729 million (USD 102 million). The agreement also includes provisions for Hansoh to pay Lupeng double-digit royalties based on future net sales of the drug.
LP-168 is currently under evaluation in multiple clinical trials, with the most advanced being a pivotal Phase II regulatory study for tumor treatments in China.- Flcube.com
